Polycystic ovary syndrome (PCOS) is a complex, multisystemic condition characterized by reproductive, metabolic and dermatologic manifestations, including hyperandrogenism and ovulatory dysfunction. Despite its prevalence and significant impact on quality of life, PCOS remains underdiagnosed and poorly managed due to its ...
Dr Svenja Nölting shares how her international experiences and dedicated mentors shaped her career in neuroendocrine oncology, discusses the profound impact of hormones on the body, and highlights the future of precision medicine in tailoring treatments for endocrine disorders.
This year the fields of paediatric and adult endocrinology are coming together in a new collaboration. The European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) will co-host their first-ever joint Congress on 10–13 May 2025 at the Bella Centre in Copenhagen, Denmark. This unique event, with the theme ‘Connecting Endocrinology Across the Life Course’, will unite specialists from across the world to foster collaboration, share knowledge and advance clinical care.
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age and is characterized by hyperandrogenism, anovulation and insulin resistance (IR).1 Women with PCOS have a high risk of developing type 2 diabetes (T2D), dyslipidaemia, hypertension and ...
Dry eye disease (DED) is known as dry eye syndrome (DES) or keratoconjunctivitis sicca. According to the Tear Film and Ocular Surface Society’s Dry Eye Workshop II (TFOS DEWS II), it constitutes a multifactorial disease of the ocular surface, ...
Polycystic ovary syndrome (PCOS) is a multifactorial, multifaceted syndrome that affects women across all ages from adolescence to post-menopause. It is reported to be the most common endocrinopathy in women of the reproductive age group.1 The nature of this syndrome ...
‘Closed-loop’ systems mark a significant advancement in managing type 1 diabetes. These systems which continuously monitor glucose levels and automatically deliver insulin through a pump, help many individuals with type 1 diabetes maintain optimal glucose levels with greater ease. In this episode, we explore the progress, challenges and impact of these innovative technologies with Endocrinology Clinical Pharmacy Specialist, Dr Diana Isaacs, and highlight their future potential.
Members of the endocrinology community gathered in Stockholm, Sweden, for the 26th European Congress of Endocrinology (ECE 2024), eager to explore the latest advancements and exchange knowledge and insights. Here are some of the standout abstracts that captured our attention:
Metformin Metformin has been recommended as the first-line glucose-lowering agent for the management of type 2 diabetes (T2D) for several decades due to its efficacy and safety profile.1–3 In fact, metformin has been widely used as an insulin-sensitizing agent for ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...
Gestational diabetes mellitus (GDM) is generally defined as “any degree of glucose tolerance with onset or first recognition during pregnancy”.1 It currently is one of the diseases with the highest morbidity among pregnant women.2 Determining its prevalence has been a ...
Despite the increasing body of knowledge of treatment strategies for diabetes, many patients with type 2 diabetes mellitus (T2DM) are still in a persistent state of poor glycaemia.1,2 In clinical practice, achieving optimal glycaemic targets is challenging; the reasons are ...
Periodontitis is a chronic inflammatory disease of the periodontium, or the supportive tissues around the tooth, which includes the gingival tissue, alveolar bone, cementum and the periodontal ligament.1 Caused by pathogenic bacteria, this disease has been recognized for at least 5,000 ...
Acromegaly is a chronic disease caused by an excess of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).1,2 Besides facial and acral changes, systemic complications lead to decreased quality of life and survival rates.3 The primary goal of acromegaly treatment ...
Type 2 diabetes (T2D) is one of the most common chronic noncommunicable diseases, its incidence is exponentially increasing and is one of the leading causes of morbidity and mortality worldwide.1 As of 2021, T2D ranked among the top causes of ...
Acromegaly is the clinical consequence of chronic excessive exposure of the tissues to growth hormone (GH) and its second messenger, insulin-like growth factor-I (IGF-I). The excess GH secretion is almost exclusively secondary to a GH-secreting pituitary adenoma (somatotropinomas); however, excess ...
Hypertension affects up to 40% of the adult population worldwide,1 and according to the World Health Organization’s 2021 estimates, globally 1.28 billion adults between 18 and 79 years are affected.2 Of these, 85% have essential hypertension3 and the remainder have secondary hypertension, which is potentially ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.